Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- UCB
- Novartis
Comparative performance (base 100)
Each asset is worth 100 at October 20, 2025; a value of 120 means +20% since that date (latest common date: October 16, 2026).
Each performance is calculated in the asset's trading currency, without currency conversion.
Indicators
"Not applicable" indicates a metric that has no meaning for this type of asset: it should not be compared.
| Indicator | UCBStock | NovartisStock |
|---|---|---|
| Performance and risk | ||
| Performance over the periodChange in price between the first and last common dates. | −19.2% | +19.7% |
| Annualized performanceAverage annual return that would produce the same total performance. | −19.4% | +20.0% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 33.4% | 23.5% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −30.7% | −15.0% |
| Sharpe RatioReturn achieved above the risk-free rate (5.10%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | -0.59 | 0.78 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −3.5% | −2.2% |
| Fundamentals | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 39.01B € | 237.02B CHF |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 17.9 | 23.8 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 4.6 | 4.2 |
| Net marginShare of revenue retained as profit. | 25.7% | 22.5% |
| Return on equityReturn on equity (ROE). | 20.6% | 30.3% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +22.5% | +0.8% |
| Dividend yieldAnnual dividend relative to the share price. | 0.71% | 2.97% |
| Debt / equityFinancial debt relative to shareholders' equity. | 31% | 117% |
Correlations over the period
From −1 to 1: close to 1, the two assets rise and fall together; close to 0, they move independently.
- UCB / Novartis0.43
Information provided for educational purposes only. It does not constitute investment advice or a personalized recommendation. Past performance is no guarantee of future results.